Serina Therapeutics Announces POZ Polymer Technology License Agreement With Pfizer

Author: Benzinga Newsdesk | November 17, 2023 09:02am

• Provides access to Serina POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations
  
   

HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina's POZ polymer technology.

"We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities," stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. "The license agreement represents an important milestone for Serina."

Posted In: AGE PFE